Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MRI Discrimination of Brain Lesions

Differentiating perivenous lesions from microangiopathic lesions

Publish date:: December 15, 2015

3-T T2*-weighted brain MRI distinguishes perivenous MS lesions from microangiopathic lesions, according to a study of 40 patients. Rules were developed in a test cohort of 10 patients with MS and 10 patients with microangiopathic white matter lesions. Rules were validated in 13 patients with MS and 7 patients with microangiopathic white matter lesions. Researchers found:

• Within the test cohort, all patients with MS had central veins visible in > 45% of brain lesions, while the rest had central veins visible in < 45% of lesions.

• By applying diagnostic rules to the validation cohort, all remaining patients were correctly categorized.

Citation: Mistry N, Abdel-Fahim R, Samaraweera A, et al. Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions. [Published online ahead of print December 10, 2015]. Mult Scler. doi: 10.1177/1352458515616700.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,